Nicholas I Simon, MD MSc

📬 The Milan Consensus paper on Clinical CR definition & Endpoints for next-gen bladder-sparing trials is out in @JCO_ASCO @ASCO | following the @SanRaffaeleMI #GURetreat24 Co-sponsored by @IBCG_BladderCA @GTumors It was a tremendous multidisciplinary effort involving friends/KOL from various fields, pt advocates @BladderCancerUS @WorldBladderCan Pharma Industries & @FDA #EMA proving insights ✅ cCR should be rigorously based on imaging + biopsy + urinary citology ✅cCR still immature as primary endpoint for registration trials (good for esploratory studies) ✅ EFS good for registration trials ✅ EFS should capture ANY type of event including HG bladder relapses 🛜 role of biomarkers (ctDNA/utDNA) still to conceive in this clinical setting but likely to become the next 🧩 @MyUniSR @UroDocAsh @SpiessPhilippe @sonpavde #MattGalsky @#bladdercancer #endpoints #clinicalresearch @urotoday @OncLive @OncoAlert @Larvol

#BCANTT25 proud of our Medical Oncology fellow Miles Hsu who received the the 2025 John Quale Travel award for our work in the development of a clinical trial for bladder preservation in MIBC. Congratulations to him and to all the outstanding fellows! @BladderCancerUS

Opening soon at the NIH!! E-VIRTUE, A Phase 2 Trial of Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors. @apolo_andrea @theNCI @NicholasISimon @DrAndreKydd @SaadAtiq24 doi.org/10.1080/147966…

Very proud of our own @SaadAtiq24 @theNCI senior fellow presenting data on the Prevalence of Histology-Agnostic Biomarkers in Pure Squamous Cell Carcinomas of the #Bladder showing 1/3 of patients with TMB-High @ASCO #ASCO25 @carisls

@bergsa83 @apolo_andrea @ASCO @ALLIANCE_org Thanks Dr @bergs83 for showing our work!

Standing in for Dr Simon and @apolo_andrea for our poster at #GU25 @ASCO @ALLIANCE_org regarding rare cancer treatment preferences , the right answer, we need trials!

We have several accruing #ClinicalTrials for patients with #SmallCell #BladderCancer 1. #Lurbi +/- #Avelumab LASER clinicaltrials.gov/study/NCT06228… 2. #SG +/- #Atezo SMART clinicaltrials.gov/study/NCT06161… 3. #CaboNivoIpi ICONIC clinicaltrials.gov/study/NCT03866… ncimo_referrals@mail.nih.gov / ☎️240-760-6006

Happy holidays from the NCI #BladderCancer Research Team! @nciccr_gmb @NCICCR_MOS @NCICCR_UroOnc @theNCI

Calling GU junior faculty & fellows! 📣 Apply for the 2025 GU Early Career Thought Leaders conference in Philadelphia 3/6-3/8, led by me & @zklaassen_md. Secure your spot for 2 days of professional development & networking: forms.gle/jMG7iKfAYomuad… @OncoAlert @SUO_YUO #SUO24

Patient Preferences for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma. What is most important to patients regarding their experiences of disease burden and treatment #BladderCancer ⁦@NicholasISimon⁩ link.springer.com/article/10.100…

Very proud of this #ClinicalTrial of Cabozantinib/Nivolumab #CaboNivo & Cabozantinib/ Nivolumab/Ipilimumab #CaboNivoIpi published @JCO_ASCO, that includes #rareGUtumors & took years to complete but laid the foundation for many future trials in oncology gcc02.safelinks.protection.outlook.com/?url=https%3A%…

A study in BMJ Oncology suggests MMR-D/MSI-H urothelial cancer may confer high sensitivity to immunotherapy. This could spare patients the morbidity of radical surgery and the toxicities of chemotherapy. @apolo_andrea @EliasChandran @GMIannantuonoMD bmjoncology.bmj.com/content/3/1/e0…

Great audience participation in #AUA24 #UTUC course with ⁦@NicholasISimon⁩ ⁦@HongTruongMD⁩ Jonathan Coleman. Much progress and much on the horizon! ⁦@AmerUrological⁩ ⁦@PSH_Urology⁩ ⁦@theNCI⁩ ⁦@MSKCancerCenter⁩

This Friday at @asco #GU24 Dr. Andrea Apolo @apolo_andrea @nciccr_gmb @NCIResearchCtr will present the results from the phase 3 AMBASSADOR of adjuvant Pembro in urothelial carcinoma @ALLIANCE_org

Congratulations to Dr. Apolo @apolo_andrea @theNCI and team.

We have a fantastic team of rising ⭐️s @EliasChandran @GMIannantuonoMD @NicholasISimon @NCIResearchCtr presenting our #BladderCancer posters on 1]mismatch repair deficiency & MSI 2]Olaparib biomarker-selected TPS 3]M7824 +NHS-IL12 +/-XRT study 4] AI with PET/CT @ASCO #ASCO23

We discuss the triple combination of Nivolumab + Ipilimumab + Cabozantinib in Advanced #RenalCellCarcinoma: Results from a Discontinued Arm of the Phase 3 #CheckMate9ER ⁦@EliasChandran⁩ @GMIannantuonoMD @NicholasISimon ⁦⁦@urotoday⁩ ⁦ urotoday.com/recent-abstrac…

@d_dressler92 This helped me decide who needed cultures when I was covering overnight: jamanetwork.com/journals/jama/…

Hey #MedTwitter, what are you some of your favorite review articles? Just a new PGY-1 trying to work on my knowledge base!

A rich 1-pager #SARSCoV2 vaccine infographic (I've divided in 2) which nicely deconstructs the complex, high- velocity race washingtonpost.com/graphics/2020/… by @asteckelberg @Carolynyjohnson @gabrielflorit @chrisalcantara @PostGraphics

We need physicians of color in all medical specialties, now more than ever. The move to P/F for @TheUSMLE Step 1 could bring us closer to achieving #DiversityinMedicine. Honored to share thoughts with @DrQuinnCapers4 + @UREssien. Out now in @NEJM: nejm.org/doi/full/10.10…